Is a complete ESLA research report available?

No complete published report is available for Estrella Immunopharma, Inc. (ESLA) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Estrella Immunopharma, Inc. (ESLA)

NASDAQ: ESLA · USD

$0.72

-0.06 (-7.6%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first ESLA analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	31M
Net income (ttm)	-13.3M
EPS (ttm)	-$0.35
Shares out	43M
Volume	32,975
Beta	0.86

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -13.3M
EPS (ttm): -$0.35
Market cap: 31M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All ESLA indicators

Market & fundamental data

Available fields

146

Groups with data

Currency

USD

Showing 146 of 146 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001844417
Company name	Estrella Immunopharma, Inc.
Country	United States
Country code	US
Cusip	297584104
Enterprise value	$29.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US2975841048
Last refreshed	2026-07-31
Market cap	$31M
Market cap category	Nano-Cap
Price	$0.72
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2836
Symbol	ESLA
Website	https://www.estrellabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-42.76%

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-13.3M
Net Income Growth Years	0%
ROA	-271.5
ROCE	251.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-23.41%
Cagr3y	-58.47%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$3.7M
Cash	$1.9M
Current Assets	$2.2M
Current Liabilities	$8.9M
Debt	$0
Equity	$-5.3M
Liabilities	$8.9M
Long Term Assets	$1.5M
Long Term Liabilities	$0
Net Cash	$1.9M
Net Cash By Market Cap	$6.22
Net Cash Growth	368.42%
Tangible Book Value	$-5.3M
Tangible Book Value Per Share	$-0.12
WACC	8.97

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.24
Net Working Capital	$-8.7M
Quick ratio	0.22
Working Capital	$-6.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.23%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-23.39%
200-day SMA	1.4
3Y total return	-92.84%
50-day SMA	0.97
50-day SMA vs 200-day SMA	50under200
All Time High	33
All Time High Change	-97.82%
All Time High Date	2023-09-01
All Time Low	0.63
All Time Low Change	14.3%
All Time Low Date	2024-10-31
ATR	0.08
Beta	0.86
Beta1y	3.74
Beta2y	1.82
Ch YTD	-53.84
High	0.76
High52	3.15
High52 Date	2025-11-04
High52ch	-77.14%
Low	0.72
Low52	0.69
Low52 Date	2026-07-28
Low52ch	4.5%
Ma50ch	-26.04%
Price vs 200-day SMA	-48.49%
RSI	34.05
RSI Monthly	37.06
RSI Weekly	37.53
Sharpe ratio	0.27x
Sortino ratio	0.5
Total Return	-5.23%
Tr YTD	-53.84
Tr1m	-30.09%
Tr1w	-5.8%
Tr3m	-51.01%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-0.12
Operating Income	$-13.3M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	14,110,087%
Float Percent	32.79%
Shares Insiders	1.87%
Shares Institutions	2.52%
Shares Out	43,034,228
Shares Qo Q	11.36%
Shares Yo Y	5.23%
Short Float	0.39%
Short Ratio	1.31
Short Shares	0.13

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted OCF	-8,624,301
Average Volume	42,434x
Bv Per Share	-0.12
Ch1m	-30.09
Ch1w	-5.8
Ch1y	-23.39
Ch3m	-51.01
Ch3y	-92.84
Ch6m	-33.32
Change	-7.57%
Change From Open	-5.24
Close	0.78
Days Gap	-2.46
Dollar Volume	23,745.3
Earnings Date	2026-08-12
Earnings Time	bmo
EBIT	$-13.3M
EBITDA	$-13.3M
EPS	$-0.35
F Score	2
Financing CF	9,523,639
Fiscal Year End	December
Founded	2,021
Income Tax	$825
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-18
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-18
Ma150	1.19
Ma150ch	-39.33%
Ma20	0.83
Ma20ch	-13.7%
Net CF	1,505,931
Next Earnings Date	2026-08-11
Open	0.76
Optionable	No
Position In Range	0
Price Date	2026-07-30
Relative Volume	0.78x
Share Based Comp	606,593
Tr6m	-33.32%
Us State	California
Volume	32,975

Estrella Immunopharma, Inc. (ESLA)

Coverage state: Market snapshot only — no published research

Generate the first ESLA analysis

Price

Financial snapshot

Fair-value bridge

Latest news · ESLA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ESLA indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ESLA

Frequently asked questions